The Phase III ORACAL trial evaluating Ostora tablets (calcitonin oral), from Tarsa Therapeutics, for the treatment of postmenopausal Osteoporosis, has...
Calcitonin is indicated for: • Prevention of acute bone loss due to sudden immobilisation such as in patients with recent osteoporotic fractures. • For the treatment of Paget's disease, only in patients who do not respond to alternative treatments or for whom such treatments are not suitable, for example those with severe renal impairment • Treatment of hypercalcemia of malignancy.
Calcitonin is indicated for: • Prevention of acute bone loss due to sudden immobilisation such as in patients with recent osteoporotic fractures • For the treatment of Paget's disease, only in patients who do not respond to alternative treatments or for whom such treatments are not suitable, for example those with severe renal impairment • Treatment of hypercalcemia of malignancy